EQUITY ALERT: Rosen Law Firm Reminds Abeona Therapeutics Inc. Investors of Important Deadline in Class Action
December 23 2016 - 4:27PM
Business Wire
Rosen Law Firm, a global investor rights law firm, reminds
purchasers of: (1) PlasmaTech Biopharmaceuticals, Inc. securities
from March 31, 2015 through June 19, 2015, both dates inclusive
(the “PlasmaTech Class Period”); and/or (2) Abeona Therapeutics
Inc. securities (NASDAQ:ABEO) from June 22, 2015 through December
9, 2016, both dates inclusive (the “Abeona Class Period” and
together with the PlasmaTech Class Period, the “Class Period”) of
the important February 14, 2017 lead plaintiff deadline in the
class action. The lawsuit seeks to recover damages for Abeona
investors under the federal securities laws.
To join the Abeona class action, go to
http://www.rosenlegal.com/cases-1009.html or call Phillip Kim, Esq.
or Kevin Chan, Esq. toll-free at 866-767-3653 or email
pkim@rosenlegal.com or kchan@rosenlegal.com for information on the
class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A
CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU
RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO
NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants
made false and/or misleading statements and/or failed to disclose
that: (1) the science behind Abeona’s proposed gene therapy
treatment for Sanfilippo syndrome is unviable; (2) Steven H.
Rouhandeh, Abeona’s Executive Chairman and Principal Executive
Officer, previously worked in a high ranking position for a biotech
promoter who was convicted of securities fraud and involved in
manipulating biotech stocks; and (3) as a result, Defendants’
statements about Abeona’s business, operations and prospects were
materially false and misleading and/or lacked a reasonable basis at
all relevant times. On December 12, 2016, analyst firm Mako
Research published a report on Abeona asserting, among other
things, that Abeona’s science underpinning its gene therapy
approach is unviable and Steven H. Rouhandeh previously worked in a
position of authority at D. Blech & Co.—a firm named after
now-convicted felon David Blech. On this news, shares of Abeona
fell $0.70 per share or over 13% from its previous closing price to
close at $4.45 per share on December 12, 2016, damaging
investors.
A class action lawsuit has already been filed. If you wish to
serve as lead plaintiff, you must move the Court no later than
February 14, 2017. If you wish to join the litigation, go to
http://www.rosenlegal.com/cases-1009.html or to discuss your rights
or interests regarding this class action, please contact Phillip
Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or
via email at pkim@rosenlegal.com or kchan@rosenlegal.com. Attorney
Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn:
https://www.linkedin.com/company/the-rosen-law-firm or on Twitter:
https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161223005357/en/
Laurence Rosen, Esq.Phillip Kim, Esq.Kevin Chan, Esq.The Rosen
Law Firm, P.A.275 Madison Avenue, 34th FloorNew York, NY 10016Tel:
(212) 686-1060Toll Free: (866) 767-3653Fax: (212)
202-3827lrosen@rosenlegal.compkim@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024